Home » Clinical Trials »  Search Clinical Trials

Therapeutic Areas:  |  Dermatology  |  Immunology  |  Family Medicine

Search Medical Condition
Please enter condition
Please choose location from dropdown
Clear Trial Filters

Atopic Dermatitis Clinical Trials

A listing of Atopic Dermatitis medical research trials actively recruiting patient volunteers. Search for closest city to find more detailed information on a research study in your area.

RESULTS

Found (4) clinical trials

Topical Application of BMX-010 in Subjects With Atopic Dermatitis and Plaque Psoriasis

This is a Phase 2, randomized, multicenter, placebo-controlled study sponsored by BioMimetix JV, LLC (BMX). It is a double-blind parallel cohort study designed to determine the safety and efficacy of BMX-010 (0.03%) relative to Placebo in subjects with atopic dermatitis and psoriasis. Subjects will be queried regarding adverse events (AEs) ...

Phase

Phase 2B Study to Evaluate ASN002 in Subjects With Moderate to Severe Atopic Dermatitis

This is study is a placebo controlled study where subjects with moderate to severe atopic dermatitis will be randomized (1:1:1:1) to receive ASN002 at 40 mg, 60 mg, or 80 mg, or placebo once daily for 12 weeks. Eligible subjects will get the opportunity to enroll in the 24 month ...

Phase

BioDay Registry: Data Collection Regarding Dupixent in Patients With Atopic Dermatitis in Daily Practice

Atopic Dermatitis (AD) is the most common chronic inflammatory skin disease in the Netherlands with more than 400.000 patients suffering from this disease. For patients with difficult to treat AD, treatment options are limited. Although the Dutch AD Guideline recommends oral immunosuppressive drugs in difficult to treat AD, both label ...

Phase N/A

A Phase II Study of MABp1 in Patients With Moderate to Severe Atopic Dermatitis

Phase 2, Open label, dose escalation study of two dose cohorts of MABp1 in patients with moderate to severe atopic dermatitis. The study is multicenter, and will consist of two dose levels: MABp1 administered subcutaneously at a dose of 200 mg weekly (4 doses) and MABp1 administered subcutaneously at a ...

Phase